Related references
Note: Only part of the references are listed.Using genetically engineered mouse models to validate candidate cancer genes and test new therapeutic approaches
Martine H. van Miltenburg et al.
CURRENT OPINION IN GENETICS & DEVELOPMENT (2012)
ENIGMA-Evidence-Based Network for the Interpretation of Germline Mutant Alleles: An International Initiative to Evaluate Risk and Clinical Significance Associated with Sequence Variation in BRCA1 and BRCA2 Genes
Amanda B. Spurdle et al.
HUMAN MUTATION (2012)
Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR
Anirudh Prahallad et al.
NATURE (2012)
A pipeline for the generation of shRNA transgenic mice
Lukas E. Dow et al.
NATURE PROTOCOLS (2012)
A SUMOylation-Dependent Transcriptional Subprogram Is Required for Myc-Driven Tumorigenesis
Jessica D. Kessler et al.
SCIENCE (2012)
High-Throughput Detection of Actionable Genomic Alterations in Clinical Tumor Samples by Targeted, Massively Parallel Sequencing
Nikhil Wagle et al.
CANCER DISCOVERY (2012)
Phase II, Open-Label, Single-Arm Trial of Imatinib Mesylate in Patients With Metastatic Melanoma Harboring c-Kit Mutation or Amplification
Jun Guo et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Deconstructing the molecular portraits of breast cancer
Aleix Prat et al.
MOLECULAR ONCOLOGY (2011)
Integrated genomic analyses of ovarian carcinoma
D. Bell et al.
NATURE (2011)
Combating trastuzumab resistance by targeting SRC, a common node downstream of multiple resistance pathways
Siyuan Zhang et al.
NATURE MEDICINE (2011)
Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy
Eric A. Collisson et al.
NATURE MEDICINE (2011)
Why don't we get more cancer? A proposed role of the microenvironment in restraining cancer progression
Mina J. Bissell et al.
NATURE MEDICINE (2011)
A public genome-scale lentiviral expression library of human ORFs
Xiaoping Yang et al.
NATURE METHODS (2011)
Crizotinib
Alice T. Shaw et al.
NATURE REVIEWS DRUG DISCOVERY (2011)
Iniparib plus Chemotherapy in Metastatic Triple-Negative Breast Cancer.
Joyce O'Shaughnessy et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Pathway Commons, a web resource for biological pathway data
Ethan G. Cerami et al.
NUCLEIC ACIDS RESEARCH (2011)
Mutation of a single allele of the cancer susceptibility gene BRCA1 leads to genomic instability in human breast epithelial cells
Hiroyuki Konishi et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
Exome sequencing identifies a spectrum of mutation frequencies in advanced and lethal prostate cancers
Akash Kumar et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
Differential Inhibitor Sensitivity of Anaplastic Lymphoma Kinase Variants Found in Neuroblastoma
Scott C. Bresler et al.
SCIENCE TRANSLATIONAL MEDICINE (2011)
EGFR mutation detection in NSCLC-assessment of diagnostic application and recommendations of the German Panel for Mutation Testing in NSCLC
Roland Penzel et al.
VIRCHOWS ARCHIV (2011)
Inference of patient-specific pathway activities from multi-dimensional cancer genomics data using PARADIGM
Charles J. Vaske et al.
BIOINFORMATICS (2010)
Integrative Genomic Profiling of Human Prostate Cancer
Barry S. Taylor et al.
CANCER CELL (2010)
Macrophage Diversity Enhances Tumor Progression and Metastasis
Bin-Zhi Qian et al.
CELL (2010)
Treatment Options for Patients With Chronic Myeloid Leukemia Who Are Resistant to or Unable to Tolerate Imatinib
Brady Stein et al.
CLINICAL THERAPEUTICS (2010)
A review of erlotinib - an oral, selective epidermal growth factor receptor tyrosine kinase inhibitor
Renuka Iyer et al.
EXPERT OPINION ON PHARMACOTHERAPY (2010)
APPLICATIONS OF NEXT-GENERATION SEQUENCING Sequencing technologies - the next generation
Michael L. Metzker
NATURE REVIEWS GENETICS (2010)
Automated Network Analysis Identifies Core Pathways in Glioblastoma
Ethan Cerami et al.
PLOS ONE (2010)
Detection of inherited mutations for breast and ovarian cancer using genomic capture and massively parallel sequencing
Tom Walsh et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
PIK3CA mutations associated with gene signature of low mTORC1 signaling and better outcomes in estrogen receptor-positive breast cancer
Sherene Loi et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Non-germline genetically engineered mouse models for translational cancer research
Joerg Heyer et al.
NATURE REVIEWS CANCER (2010)
Novel Agents on the Horizon for Cancer Therapy
Wen W. Ma et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2009)
Ligand-Independent HER2/HER3/PI3K Complex Is Disrupted by Trastuzumab and Is Effectively Inhibited by the PI3K Inhibitor GDC-0941
Teemu T. Junttila et al.
CANCER CELL (2009)
A Genome-wide RNAi Screen Identifies Multiple Synthetic Lethal Interactions with the Ras Oncogene
Ji Luo et al.
CELL (2009)
PIK3CA Mutation Associates with Improved Outcome in Breast Cancer
Kevin Kalinsky et al.
CLINICAL CANCER RESEARCH (2009)
Resistance to Trastuzumab in Breast Cancer
Paula R. Pohlmann et al.
CLINICAL CANCER RESEARCH (2009)
Lapatinib Combined With Letrozole Versus Letrozole and Placebo As First-Line Therapy for Postmenopausal Hormone Receptor-Positive Metastatic Breast Cancer
Stephen Johnston et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers.
Peter C. Fong et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Knockin of mutant PIK3CA activates multiple oncogenic pathways
John P. Gustin et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
Inhibition of Hedgehog Signaling Enhances Delivery of Chemotherapy in a Mouse Model of Pancreatic Cancer
Kenneth P. Olive et al.
SCIENCE (2009)
Targeting cancer with small molecule kinase inhibitors
Jianming Zhang et al.
NATURE REVIEWS CANCER (2009)
Phosphatidylinositol 3-Kinase Hyperactivation Results in Lapatinib Resistance that Is Reversed by the mTOR/Phosphatidylinositol 3-Kinase Inhibitor NVP-BEZ235
Pieter J. A. Eichhorn et al.
CANCER RESEARCH (2008)
Enabling personalized cancer medicine through analysis of gene-expression patterns
Laura J. van 't Veer et al.
NATURE (2008)
Comprehensive genomic characterization defines human glioblastoma genes and core pathways
L. Chin et al.
NATURE (2008)
Lapatinib: A sword with two edges
Laszlo Kopper
PATHOLOGY & ONCOLOGY RESEARCH (2008)
Core signaling pathways in human pancreatic cancers revealed by global genomic analyses
Sian Jones et al.
SCIENCE (2008)
Tamoxifen-stimulated growth of breast cancer due to p21 loss
Abde M. Abukhdeir et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Dasatinib: A tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia
Michael Steinberg
CLINICAL THERAPEUTICS (2007)
A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer
Katrien Berns et al.
CANCER CELL (2007)
Knock-in of mutant K-ras in nontumorigenic human epithelial cells as a new model for studying K-ras-mediated transformation
Hiroyuki Konishi et al.
CANCER RESEARCH (2007)
Drug therapy: Trastuzumab - Mechanism of action and use in clinical practice
Clifford A. Hudis
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Chromosomally unstable mouse tumours have genomic alterations similar to diverse human cancers
Richard S. Maser et al.
NATURE (2007)
Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia
Brian J. Druker et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes
Richard M. Neve et al.
CANCER CELL (2006)
Macrophages regulate the angiogenic switch in a mouse model of breast cancer
Elaine Y. Lin et al.
CANCER RESEARCH (2006)
Genomic and transcriptional aberrations linked to breast cancer pathophysiologies
Koei Chin et al.
CANCER CELL (2006)
Overcoming trastuzumab resistance in HER2-overexpressing breast cancer cells by using a novel celecoxib-derived phosphoinositide-dependent kinase-1 inhibitor
Ping-Hui Tseng et al.
MOLECULAR PHARMACOLOGY (2006)
Discovery and development of sorafenib: a multikinase inhibitor for treating cancer
Scott Wilhelm et al.
NATURE REVIEWS DRUG DISCOVERY (2006)
Genome-scale loss-of-function screening with a lentiviral RNAi library
David E. Root et al.
NATURE METHODS (2006)
Targeting tumor-associated macrophages as a novel strategy against breast cancer
Yunping Luo et al.
JOURNAL OF CLINICAL INVESTIGATION (2006)
Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL
Hagop Kantarjian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
A model of acquired autoresistance to a potent ErbB2 tyrosine kinase inhibitor and a therapeutic strategy to prevent its onset in breast cancer
Wenle Xia et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
Sunitinib malate for the treatment of solid tumours: a review of current clinical data
Robert J. Motzer et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2006)
ARACNE: An algorithm for the reconstruction of gene regulatory networks in a mammalian cellular context
AA Margolin et al.
BMC BIOINFORMATICS (2006)
Macrophages: Obligate partners for tumor cell migration, invasion, and metastasis
J Condeelis et al.
CELL (2006)
Copy number aberrations in mouse breast tumors reveal loci and genes important in tumorigenic receptor tyrosine kinase signaling
JG Hodgson et al.
CANCER RESEARCH (2005)
Determination of HER2 gene amplification by fluorescence in situ hybridization and concordance with the clinical trials immunohistochemical assay in women with metastatic breast cancer evaluated for treatment with trastuzumab
N Dybdal et al.
BREAST CANCER RESEARCH AND TREATMENT (2005)
Chromosome-wide and promoter-specific analyses identify sites of differential DNA methylation in normal and transformed human cells
M Weber et al.
NATURE GENETICS (2005)
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
H Farmer et al.
NATURE (2005)
Comparative analysis of two clinically active BCR-ABL kinase inhibitors reveals the role of conformation-specific binding in resistance
MR Burgess et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Development of Herceptin resistance in breast cancer cells
T Kute et al.
CYTOMETRY PART A (2004)
Cancer genes and the pathways they control
B Vogelstein et al.
NATURE MEDICINE (2004)
Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome
KP Olive et al.
CELL (2004)
An oligonucleotide microchip for genome-wide microRNA profiling in human and mouse tissues
CG Liu et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
A paracrine loop between tumor cells and macrophages is required for tumor cell migration in mammary tumors
J Wyckoff et al.
CANCER RESEARCH (2004)
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib
TJ Lynch et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Efficacy and safety of imatinib in adult patients with c-kit-positive acute myeloid leukemia
T Kindler et al.
BLOOD (2004)
Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment
R Bhatia et al.
BLOOD (2003)
Elevated levels of epidermal growth factor receptor/c-erbB2 heterodimers mediate an autocrine growth regulatory pathway in tamoxifen-resistant MCF-7 cells
JM Knowlden et al.
ENDOCRINOLOGY (2003)
The antiepidermal growth factor receptor agent gefitinib (ZD1839/Iressa) improves antihormone response and prevents development of resistance in breast cancer in vitro
JMW Gee et al.
ENDOCRINOLOGY (2003)
Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors
GD Demetri et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications
T Sorlie et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2001)
Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia.
BJ Druker et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.
DJ Slamon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling
AA Alizadeh et al.
NATURE (2000)
Lessons learned from the development of an Abl tyrosine kinase inhibitor for chronic myelogenous leukemia
BJ Druker et al.
JOURNAL OF CLINICAL INVESTIGATION (2000)
Share Paper
